Superseded public profile

FDA-approved↗Metabolic↗

Superseded · version 3: Liraglutide↗

Related names recorded in this version: Saxenda↗

A GLP-1 receptor agonist. This profile cites a U.S. label record.↗

This is preserved historical wording.
It is no longer the current profile. Read the canonical profile and its correction notice.
Update · July 29, 2026

We added a product-name lookup term that the cited FDA label communication connects to liraglutide. The profile's status did not change. 2

What this version reported

The cited DailyMed label identifies Liraglutide and contains the product's official indications and warnings. This profile links to the label without restating it as medical guidance.↗

Organizations named in cited records:
  • U.S. National Library of Medicine↗

Sources for this version

  1. 1
    Liraglutide injection, solution · SPL version 6 · published 2026-07-14 ↗

    DailyMed · U.S. National Library of Medicine · Official source · Source checked July 22, 2026

  2. 2
    FDA requests removal of suicidal behavior and ideation warning from certain GLP-1 RA labels ↗

    U.S. Food and Drug Administration · Official source · Source checked July 29, 2026